As of 2026-04-05, the Intrinsic Value of Helix Biopharma Corp (HBP.TO) is -0.38 CAD. This HBP.TO valuation is based on the model Peter Lynch Fair Value. With the current market price of 1.70 CAD, the upside of Helix Biopharma Corp is -122.26%.
Based on its market price of 1.70 CAD and our intrinsic valuation, Helix Biopharma Corp (HBP.TO) is overvalued by 122.26%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -0.38 - -0.38 | -0.38 | -122.26% |
| P/E | (0.03) - (0.06) | (0.04) | -102.4% |
| DDM - Stable | (1.12) - 46.04 | 22.46 | 1221.3% |
| DDM - Multi | (1.16) - 37.55 | (2.41) | -241.8% |
| Market Cap (mil) | 129.85 |
| Beta | 2.68 |
| Outstanding shares (mil) | 76.38 |
| Enterprise Value (mil) | 129.70 |
| Market risk premium | 5.10% |
| Cost of Equity | 5.94% |
| Cost of Debt | 5.00% |
| WACC | 5.93% |